Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor-positive/HER2-negative disease. (Abstract S5-07)
Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).
Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.
William M. Sikov, MD, of Women and Infants Hospital of Rhode Island, discusses the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).
